Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism and Disposition of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Rhesus Monkeys

Michael Meger, Elmar Richter, Wolfgang Zwickenpflug, Christiana Oehlmann, Maureen B. Hargaden, Yousif I. A-Rahim and Elliot S. Vesell
Drug Metabolism and Disposition April 1999, 27 (4) 471-478;
Michael Meger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elmar Richter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Zwickenpflug
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiana Oehlmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maureen B. Hargaden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yousif I. A-Rahim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliot S. Vesell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Metabolism and disposition of the tobacco-specificN-nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a potent rodent lung carcinogen, were studied in rhesus monkeys. In three males receiving a single i.v. dose of [5-3H]NNK (0.72 mCi; 4.6–9.8 μg/kg), urine was collected for 10 days. Within the first 24 h, 86.0 ± 0.7% of the dose was excreted. NNK-derived radioactivity was still detectable in urine 10 days after dosing (total excretion, 92.7 ± 0.7%). Decay of urinary radioactivity was biexponential with half-lives of 1.7 and 42 h. Metabolite patterns in urine from the first 6 h closely resembled those reported previously for patas monkeys; end products of metabolic NNK activation represented more than 50% of total radioactivity. At later time points, the pattern shifted in favor of NNK detoxification products (60–70% of total radioactivity in urine), mainly 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and itsO-glucuronide conjugates. One female rhesus monkey received a single i.v. dose of [5-3H]NNK (1.72 mCi; 28.4 μg/kg) under isoflurane anesthesia; biliary excretion over 6 h (0.6% of the dose) was 10 times less than predicted by our previously reported rat model. No preferential excretion of NNAL glucuronide was observed in monkey bile. Collectively, these results suggest that the rhesus monkey could be a useful model for NNK metabolism and disposition in humans.

Footnotes

  • Send reprint requests to: Prof. Dr. Elmar Richter, Walther Straub-Institut für Pharmakologie und Toxikologie, Nussbaumstrasse 26, D-80336 München, Germany. E-mail:franky.richter{at}lrz.uni-muenchen.de

  • Rhesus monkeys were generously provided by Dr. R. Lang, Director of the Department of Comparative Medicine, The Pennsylvania State University, College of Medicine, Hershey, PA. Part of these results were presented at the 38th Spring Meeting, March 11–13 ,1997, Mainz, Germany.

  • Abbreviations used are::
    NNN
    N′-nitrosonornicotine
    NNK
    4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
    NNAL
    4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
    NNAL-Gluc
    [4-(methylnitrosamino)-1-(3-pyridyl)but-1-yl]-β-O-d-glucosiduronic acid
    NNAL-N-oxide
    4-(methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanol
    NNK-N-oxide
    4-(methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanone
    • Received September 9, 1998.
    • Accepted December 16, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (4)
Drug Metabolism and Disposition
Vol. 27, Issue 4
1 Apr 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Disposition of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Rhesus Monkeys
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolism and Disposition of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Rhesus Monkeys

Michael Meger, Elmar Richter, Wolfgang Zwickenpflug, Christiana Oehlmann, Maureen B. Hargaden, Yousif I. A-Rahim and Elliot S. Vesell
Drug Metabolism and Disposition April 1, 1999, 27 (4) 471-478;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolism and Disposition of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Rhesus Monkeys

Michael Meger, Elmar Richter, Wolfgang Zwickenpflug, Christiana Oehlmann, Maureen B. Hargaden, Yousif I. A-Rahim and Elliot S. Vesell
Drug Metabolism and Disposition April 1, 1999, 27 (4) 471-478;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Functional Characterization of 29 CYP4F2 Variants
  • Exposure-toxicity relation of apatinib
  • ABC phenomenon potentiates anti-HCC efficacy
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics